@article{8a911fa926024fa2879150d2021cb3c8,
title = "Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis",
abstract = "Background: There is growing interest in white matter (WM) imaging with positron emission tomography (PET). Objectives: We studied the association of cognitive function in late multiple sclerosis (MS) with cortical and WM Pittsburgh compound-B PET (PiB-PET) binding. Methods: In the population-based Mayo Clinic Study of Aging, 24 of 4869 participants had MS (12 underwent PiB-PET). Controls were age and sex matched (5:1). We used automated or semi-automated processing for quantitative image analyses and conditional logistic regression for group differences. Results: MS patients had lower memory (p = 0.03) and language (p = 0.02) performance; smaller thalamic volumes (p = 0.003); and thinner temporal (p = 0.001) and frontal (p = 0.045) cortices on magnetic resonance imaging (MRI) than controls. There was no difference in global cortical PiB standardized uptake value ratios between MS and controls (p = 0.35). PiB uptake was lower in areas of WM hyperintensities compared to normal-appearing white matter (NAWM) in MS (p = 0.0002). Reduced PiB uptake in both the areas of WM hyperintensities (r = 0.65; p = 0.02) and NAWM (r = 0.69; p = 0.01) was associated with decreased visuospatial performance in MS. Conclusion: PiB uptake in the cortex in late MS is not different from normal age-matched controls. PiB uptake in the WM in late MS may be a marker of the large network structures{\textquoteright} integrity such as those involved in visuospatial performance.",
keywords = "PET, Pittsburgh compound-B, cognition, multiple sclerosis, myelin, thalamus",
author = "Burcu Zeydan and Lowe, {Val J.} and Schwarz, {Christopher G.} and Przybelski, {Scott A.} and Nirubol Tosakulwong and Zuk, {Samantha M.} and Senjem, {Matthew L.} and Gunter, {Jeffrey L.} and Roberts, {Rosebud O} and Mielke, {Michelle M.} and Benarroch, {Eduardo E.} and Moses Rodriguez and Machulda, {Mary M.} and Lesnick, {Timothy G.} and Knopman, {David S.} and Petersen, {Ronald C.} and Jack, {Clifford R.} and Kejal Kantarci and Kantarci, {Orhun H.}",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr B.Z. received support from the Turkish Neurological Society. Dr V.L. reports grants from NIH, Liston Foundation, and The Elsie and Marvin Dekelboum Family Foundation, during the conduct of the study; personal fees from Bayer Pharmaceuticals, grants from GE Health Care, Siemens Molecular Imaging, AVID Radiopharmaceuticals; personal fees from Piramal Imaging, outside the submitted work. Dr C.S., Mr S.P., Ms N.T., Ms S.Z. Mr J.G., Dr R.R., Dr M.M., Dr E.B., Dr M.R., Dr M.M., and Mr T.L. nothing to disclose. Mr M.S. discloses equity/options ownership in medical companies: Gilead Sciences, Inc., Inovio Pharmaceuticals, Medtronic, and PAREXEL International Corporation. Dr D.S.K. serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer{\textquoteright}s Disease Treatment Unit. He is participating in clinical trials sponsored by Lilly Pharmaceuticals and Tau Rx Pharmaceuticals. He receives research support from the NIH. Dr R.P. chaired a Data Monitoring Committee of Pfizer, Inc. and Janssen Alzheimer Immunotherapy and serves as a consultant for Hoffman La Roche, Inc., Merck, Inc., Genentech, Inc., Biogen, Inc., Eli Lilly and Co. and receives research support from the NIH (P50 AG016574 [PI] and U01 AG006786 [PI], R01 AG011378 [Co-I], and U01 AG024904 [Co-I]). Dr C.J. reports consulting services for Eli Lilly Co, funding from the NIH (R01 AG011378, U01 AG024904, RO1 AG041851, R01 AG037551, R01 AG043392, and U01 AG006786) and research support from the Alexander Family Professorship of Alzheimer{\textquoteright}s Disease Research. Dr K.K. serves on the data safety monitoring board for Pfizer Inc. and Janssen Alzheimer{\textquoteright}s Immunotherapy Takeda Global Research & Development Center, Inc. and she is funded by the NIH. Dr O.H.K gave and organized scientific presentations at meetings supported by Novartis Pharmaceuticals but has received no personal compensation, presented as an invited professor in Biogen Pharmaceuticals but received no personal compensation. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the NIH [R01 AG040042, P50 AG016574, U01 AG006786, C06 RR018898], The Minnesota Partnership for Biotechnology and Medical Genomics, The Elsie and Marvin Dekelboum Family Foundation, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer{\textquoteright}s Disease Research Program. The funding sources had no role in study design, collection, analysis, interpretation, or decision to submit this paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Publisher Copyright: {\textcopyright} 2017, {\textcopyright} The Author(s), 2017.",
year = "2018",
month = may,
day = "1",
doi = "10.1177/1352458517707346",
language = "English (US)",
volume = "24",
pages = "739--749",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",
}